Costs of administration, travelling, and productivity losses associated with hospital administration of multiple myeloma drugs in Finland-Reference-Cited by-同舟云学术

Costs of administration, travelling, and productivity losses associated with hospital administration of multiple myeloma drugs in Finland

Published:2019-02-04 Issue:4 Volume:22 Page:328-335
ISSN:1369-6998
Container-title:Journal of Medical Economics
language:en
Short-container-title:Journal of Medical Economics

Author:

Mankinen Petri¹,Vihervaara Ville²,Torvinen Saku²,Martikainen Janne¹,Soini Erkki¹

Affiliation:

1. ESiOR Oy, Kuopio, Finland;

2. Takeda Oy, Helsinki, Finland

Funder

Takeda Oy

Publisher

Informa UK Limited

Subject

Health Policy

Link

https://www.tandfonline.com/doi/pdf/10.1080/13696998.2019.1569457

Reference33 articles.

1. Multiple myeloma

2. Allogeneic Stem Cell Transplantation and Targeted Immunotherapy for Multiple Myeloma

3. The future of autologous stem cell transplantation in myeloma

4. Suomen myeloomaryhmän (FMG) hoitosuositus 11/2017 [Treatment recommendation of the Finnish Myeloma Group 11/2017]. Finnish Hematology Association. Updated 2017 Nov 1 [cited 2018 Dec 11]. Available from: https://www.hematology.fi/sites/default/files/uploads/fmg_suositus_2017_1.pdf

5. Carfilzomib, Lenalidomide, and Dexamethasone for Relapsed Multiple Myeloma

Cited by 10 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Construction of hyaluronic acid-functionalized magnolol nanoparticles for ulcerative colitis treatment;International Journal of Biological Macromolecules;2024-05

2. Real-World Health Care Services Utilization Associated With the Management of Patients With Relapsed and Refractory Multiple Myeloma in Spain: The CharisMMa Study;Clinical Lymphoma Myeloma and Leukemia;2023-10

3. Real-world evidence of multiple myeloma treated from 2013 to 2019 in the Hospital District of Helsinki and Uusimaa, Finland;Future Oncology;2023-09

4. The Burden of a Multiple Myeloma Diagnosis on Patients and Caregivers in the First Year: Western European Findings;ClinicoEconomics and Outcomes Research;2022-12

5. Oral Therapies for Multiple Myeloma;Oncology & Haematology;2022